A Study in Subjects With Retinal Detachment

Phase 1

Completed

• Conditions: Retinal Detachment

• Registration Number: NCT00210067
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

The purpose of this trial is to access the tolerability of INS37217 Intravitreal Injection when administered intravitreally in subjects with macula-on or macula-off rhegmatogenous retinal detachment (RRD).

Detailed Description

Not available

Study Timeline

• Study Start: 2001-05
• Primary Completion: 2002-06
• Study Completion: 2002-06
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-21
• Status Verified: 2015-10
• Last Update Submitted: 2015-10-08
• Last Update Posted: 2015-10-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Not specified
• Target Recruitment: 14

Inclusion Criteria

• have macula-on or macula-off rhegmatogenous retinal detachment
• are eligible for pneumatic retinopexy, with identifiable retinal breaks
• are phakic or pseudo-phakic

Exclusion Criteria

• have detachments not of a rhegmatogenous nature
• currently have blood in the vitreous, corneal opacity, or other conditions which limit the view of peripheral retina
• have evidence of intraocular inflammation (uveitis)
• have a history of current condition of uncontrollable, elevated IOP or open-angle glaucoma
• have breaks not conducive to a single procedure of pneumatic retinopexy treatment
• have proliferative vitreoretinopathy of type C or D
• have previously had a vitrectomy or require one
• have previously had a scleral buckle procedure

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
tolerability

Secondary Outcome Measures

Name	Time	Method
pharmacological activity